Search research articles
Contact Us
Filters
Showing results (101-110 of 112) with videos related to
Page
of 12
Sort By:
Bulletin Du Cancer
|
July 1, 1994
[Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults]
J Fleury, J Tortochaux, M Legros, et al.
Bone Marrow Transplantation
|
April 1, 1990
High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France
P Viens, D Maraninchi, M Legros, et al.
Bulletin Du Cancer
|
January 1, 1990
[High doses of alkylating agents and bone marrow autograft in ovarian cancer with poor prognosis: a retrospective analysis of 40 patients treated in France]
D Maraninchi, P Viens, M Legros, et al.
Lancet (London, England)
|
March 19, 1994
Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation
C Gisselbrecht, H G Prentice, A Bacigalupo, et al.
Tissue Antigens
|
July 21, 2000
Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules
S Fournel, X Huc, M Aguerre-Girr, et al.
Bone Marrow Transplantation
|
February 1, 1997
rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial
M Legros, J Fleury, J O Bay, et al.
Leukemia & Lymphoma
|
January 1, 1996
High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease
J Fleury, M Legros, P Colombat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1997
High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results
M Legros, J Dauplat, J Fleury, et al.
Leukemia & Lymphoma
|
May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission
D Blaise, M Attal, J L Pico, et al.
Blood
|
July 1, 1996
Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle
L Sutton, C Chastang, P Ribaud, et al.
Page
of 12
Search research articles
Search
Showing results (101-110 of 112) with videos related to
Sort By:
Page
of 12
Bulletin Du Cancer
|
July 1, 1994
[Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults]
J Fleury, J Tortochaux, M Legros, et al.
Bone Marrow Transplantation
|
April 1, 1990
High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: a retrospective analysis of 35 patients treated in France
P Viens, D Maraninchi, M Legros, et al.
Bulletin Du Cancer
|
January 1, 1990
[High doses of alkylating agents and bone marrow autograft in ovarian cancer with poor prognosis: a retrospective analysis of 40 patients treated in France]
D Maraninchi, P Viens, M Legros, et al.
Lancet (London, England)
|
March 19, 1994
Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation
C Gisselbrecht, H G Prentice, A Bacigalupo, et al.
Tissue Antigens
|
July 21, 2000
Comparative reactivity of different HLA-G monoclonal antibodies to soluble HLA-G molecules
S Fournel, X Huc, M Aguerre-Girr, et al.
Bone Marrow Transplantation
|
February 1, 1997
rhGM-CSF vs placebo following rhGM-CSF-mobilized PBPC transplantation: a phase III double-blind randomized trial
M Legros, J Fleury, J O Bay, et al.
Leukemia & Lymphoma
|
January 1, 1996
High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin's disease
J Fleury, M Legros, P Colombat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 1997
High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: long-term results
M Legros, J Dauplat, J Fleury, et al.
Leukemia & Lymphoma
|
May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission
D Blaise, M Attal, J L Pico, et al.
Blood
|
July 1, 1996
Factors influencing outcome in de novo myelodysplastic syndromes treated by allogeneic bone marrow transplantation: a long-term study of 71 patients Société Française de Greffe de Moelle
L Sutton, C Chastang, P Ribaud, et al.
Page
of 12